RBF Capital LLC Has $333,000 Stock Position in Allakos Inc. (NASDAQ:ALLK)

RBF Capital LLC grew its holdings in Allakos Inc. (NASDAQ:ALLK) by 45.9% during the third quarter, Holdings Channel.com reports. The firm owned 510,529 shares of the company’s stock after acquiring an additional 160,529 shares during the quarter. RBF Capital LLC’s holdings in Allakos were worth $333,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Point72 Asset Management L.P. acquired a new stake in shares of Allakos in the third quarter valued at approximately $1,143,000. FMR LLC raised its holdings in shares of Allakos by 14.6% in the third quarter. FMR LLC now owns 5,370,247 shares of the company’s stock valued at $3,508,000 after purchasing an additional 685,623 shares during the last quarter. GSA Capital Partners LLP raised its holdings in shares of Allakos by 11.9% in the third quarter. GSA Capital Partners LLP now owns 794,896 shares of the company’s stock valued at $519,000 after purchasing an additional 84,750 shares during the last quarter. Point72 DIFC Ltd acquired a new stake in shares of Allakos in the second quarter valued at approximately $25,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Allakos in the second quarter valued at approximately $55,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, JMP Securities reiterated a “market outperform” rating and issued a $3.00 price objective on shares of Allakos in a report on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $1.67.

Allakos Trading Down 1.8 %

Shares of ALLK opened at $1.10 on Friday. The company has a market cap of $98.27 million, a price-to-earnings ratio of -0.54 and a beta of 0.92. Allakos Inc. has a 1-year low of $0.54 and a 1-year high of $3.41. The company’s fifty day simple moving average is $1.00 and its 200 day simple moving average is $0.92.

Allakos (NASDAQ:ALLK) last issued its earnings results on Wednesday, November 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. As a group, research analysts forecast that Allakos Inc. will post -1.16 earnings per share for the current year.

Allakos Company Profile

Allakos Inc, a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.